重症COVID-19诱导的子痫前期样综合征的确认:一项观察性研究
这项前瞻性观察性研究在三级转诊医院纳入68例因重症COVID-19肺炎入住ICU的孕妇,按临床和实验室发现分为子痫前期组、子痫前期样综合征组和无子痫前期特征组。结果显示,53例(50.0%)不符合子痫前期诊断标准,7例(6.6%)符合子痫前期诊断且sFlt-1/PlGF比值异常(>38),8例(7.5%)符合子痫前期诊断但sFlt-1/PlGF比值正常(≤38)的子痫前期样综合征组。子痫前期组围产结局显著差于子痫前期样综合征组或无子痫前期组。
要点
- 重症COVID-19孕妇中,符合子痫前期诊断标准者可能并非真正子痫前期,而是子痫前期样综合征。
- 子痫前期样综合征组sFlt-1/PlGF比值正常(≤38),肺炎好转后多数子痫前期相关特征改善。
- 子痫前期组围产结局显著差于子痫前期样综合征组或无子痫前期组。
核心结论
- 超过50%的重症COVID-19且符合子痫前期诊断标准的孕妇可能并非子痫前期,而是子痫前期样综合征,后者可能影响高达7.5%的重症COVID-19孕妇。
- 子痫前期样综合征的围产结局可能与因COVID-19重症肺炎的血压正常孕妇相似。
- 作者建议在未来的研究和做出临床决策前,应使用sFlt-1/PlGF比值排除子痫前期样综合征。
研究设计与样本
- 前瞻性观察性研究,在三级转诊医院进行。
- 纳入标准为因COVID-19重症肺炎入住重症监护室的孕妇。
- 根据临床和实验室发现分为3组:子痫前期、子痫前期样综合征、无子痫前期特征。
- 在重症肺炎前、中、后3个时间点对3组队列进行分析比较。
- 主要结局为不良围产结局发生率及子痫前期的症状和体征,如高血压、蛋白尿、血小板减少、肝酶升高和血管生成因子升高(sFlt-1/PlGF比值)。
主要发现
- 共106例孕妇因重症肺炎入住ICU,68例纳入研究。
- 53例(50.0%)不符合子痫前期诊断标准,肺炎后继续妊娠(无子痫前期组)。
- 7例(6.6%)符合子痫前期诊断标准,sFlt-1/PlGF比值异常(>38),重症肺炎期间分娩(子痫前期组)。
- 8例(7.5%)符合子痫前期诊断标准,sFlt-1/PlGF比值正常(≤38),肺炎期间未分娩(子痫前期样综合征组)。
- 子痫前期样综合征组多数子痫前期相关特征在重症肺炎后改善,尽管未分娩。
关键数值与推荐
- 子痫前期诊断标准:符合子痫前期诊断标准且sFlt-1/PlGF比值异常(>38)。
- 子痫前期样综合征:符合子痫前期诊断标准但sFlt-1/PlGF比值正常(≤38)。
- 无子痫前期:不符合子痫前期诊断标准。
临床怎么用
- 作者建议在未来的研究和做出临床决策前,应使用sFlt-1/PlGF比值排除子痫前期样综合征。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Since the outbreak of the COVID-19 pandemic, some studies have reported an increased preeclampsia incidence in pregnant women with SARS-CoV-2 infection. Several explanations for this association have been proposed, including a preeclampsia-like syndrome induced by severe COVID-19. This syndrome was described in a small case series and has not been confirmed in larger studies, and its effect on perinatal outcomes has not been studied. OBJECTIVE: This study aimed to confirm the preeclampsia-like syndrome because of COVID-19 and to investigate its implications on pregnancy outcomes and prognosis. STUDY DESIGN: This was a prospective, observational study conducted in a tertiary referral hospital. The inclusion criteria were pregnant women admitted to the intensive care unit for severe pneumonia because of COVID-19. They were classified into 3 groups based on clinical and laboratory findings: preeclampsia, preeclampsia-like syndrome, and women without preeclampsia features. The 3 cohorts were analyzed and compared at 3 different times: before, during, and after severe pneumonia. The main outcomes were incidence of adverse perinatal outcomes and signs and symptoms of PE, such as hypertension, proteinuria, thrombocytopenia, elevated liver enzymes, and increased angiogenic factors (soluble fms-like tyrosine kinase 1-to-placental growth factor ratio). RESULTS: A total of 106 women were admitted to the intensive care unit because of severe pneumonia, and 68 women were included in the study. Of those, 53 (50.0%) did not meet the diagnostic criteria for preeclampsia and remained pregnant after pneumonia (non-preeclampsia); 7 (6.6%) met the diagnostic criteria for preeclampsia, had abnormal (>38) soluble fms-like tyrosine kinase 1-to-placental growth factor ratio (preeclampsia), and delivered during severe pneumonia, and 8 (7.5%) met the diagnostic criteria for preeclampsia, had normal (≤38) soluble fms-like tyrosine kinase 1-to-placental growth factor ratio (preeclampsia like), and did not deliver during pneumonia. Despite not having delivered, most preeclampsia-related features improved after severe pneumonia in women with preeclampsia-like syndrome. Women with preeclampsia had significantly poorer outcomes than women with preeclampsia-like syndrome or without preeclampsia. CONCLUSION: More than 50% of women with severe COVID-19 and diagnostic criteria for preeclampsia may not be preeclampsia but a preeclampsia-like syndrome, which may affect up to 7.5% of women with severe COVID-19. Preeclampsia-like syndrome might have similar perinatal outcomes to those of normotensive women with severe pneumonia because of COVID-19. For these reasons, preeclampsia-like syndrome should be excluded by using soluble fms-like tyrosine kinase 1-to-placental growth factor ratio in future research and before making clinical decisions.
引用
- Serrano B, Bonacina E, Garcia-Ruiz I, et al. Confirmation of preeclampsia-like syndrome induced by severe COVID-19: an observational study. Am J Obstet Gynecol MFM. 2022. PMID: 36195282. doi:10.1016/j.ajogmf.2022.100760
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。